GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Venus Remedies Ltd (BOM:526953) » Definitions » EBIT

Venus Remedies (BOM:526953) EBIT : ₹447 Mil (TTM As of Mar. 2024)


View and export this data going back to 2000. Start your Free Trial

What is Venus Remedies EBIT?

Venus Remedies's earnings before interest and taxes (EBIT) for the three months ended in Mar. 2024 was ₹174 Mil. Its earnings before interest and taxes (EBIT) for the trailing twelve months (TTM) ended in Mar. 2024 was ₹447 Mil.

EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. Venus Remedies's annualized ROC % for the quarter that ended in Mar. 2024 was 6.55%. Venus Remedies's annualized ROC (Joel Greenblatt) % for the quarter that ended in Mar. 2024 was 19.89%.

EBIT is also linked to Joel Greenblatt's definition of earnings yield. Venus Remedies's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Mar. 2024 was 12.38%.


Venus Remedies EBIT Historical Data

The historical data trend for Venus Remedies's EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Venus Remedies EBIT Chart

Venus Remedies Annual Data
Trend Mar15 Mar16 Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24
EBIT
Get a 7-Day Free Trial Premium Member Only Premium Member Only 36.27 555.64 366.06 380.50 447.30

Venus Remedies Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
EBIT Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 194.30 51.10 144.00 78.50 173.70

Competitive Comparison of Venus Remedies's EBIT

For the Drug Manufacturers - Specialty & Generic subindustry, Venus Remedies's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Venus Remedies's EV-to-EBIT Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Venus Remedies's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Venus Remedies's EV-to-EBIT falls into.



Venus Remedies EBIT Calculation

EBIT, sometimes also called Earnings Before Interest and Taxes, is a measure of a firm's profit that includes all expenses except interest and income tax expenses. It is the difference between operating revenues and operating expenses. When a firm does not have non-operating income, then Operating Income is sometimes used as a synonym for EBIT and operating profit.

EBIT for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was ₹447 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Venus Remedies  (BOM:526953) EBIT Explanation

1. EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

Venus Remedies's annualized ROC % for the quarter that ended in Mar. 2024 is calculated as:

ROC % (Q: Mar. 2024 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (Q: Dec. 2023 ) + Invested Capital (Q: Mar. 2024 ))/ count )
=538.4 * ( 1 - 39.78% )/( (0 + 4948.4)/ 1 )
=324.22448/4948.4
=6.55 %

where

Note: The Operating Income data used here is four times the quarterly (Mar. 2024) data.

2. Joel Greenblatt's definition of Return on Capital:

Venus Remedies's annualized ROC (Joel Greenblatt) % for the quarter that ended in Mar. 2024 is calculated as:

ROC (Joel Greenblatt) %(Q: Mar. 2024 )
=EBIT/Average of (Net fixed Assets + Net Working Capital)
=EBIT/Average of (Property, Plant and Equipment+Net Working Capital)
     Q: Dec. 2023  Q: Mar. 2024
=EBIT/( ( (Property, Plant and Equipment + Net Working Capital) + (Property, Plant and Equipment + Net Working Capital) )/ count )
=694.8/( ( (0 + max(0, 0)) + (1544 + max(1949.2, 0)) )/ 1 )
=694.8/( ( 0 + 3493.2 )/ 1 )
=694.8/3493.2
=19.89 %

where Working Capital is:

Working Capital(Q: Dec. 2023 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(0 + 0 + 0) - (0 + 0 + 0)
=0

Working Capital(Q: Mar. 2024 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(805 + 1216.9 + 695) - (441.5 + 0 + 326.2)
=1949.2

When net working capital is negative, 0 is used.

Note: The EBIT data used here is four times the quarterly (Mar. 2024) EBIT data.

3. It is also linked to Joel Greenblatt's definition of Earnings Yield:

Venus Remedies's Earnings Yield (Joel Greenblatt) % for today is calculated as:

Earnings Yield (Joel Greenblatt) %=EBIT (TTM)/Enterprise Value (Q: Mar. 2024 )
=447.3/3612.500
=12.38 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Venus Remedies EBIT Related Terms

Thank you for viewing the detailed overview of Venus Remedies's EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.


Venus Remedies (BOM:526953) Business Description

Traded in Other Exchanges
Address
Plot 51-52, Industrial Area, Phase 1, Panchkula, HR, IND, 134113
Venus Remedies Ltd is an Indian drug manufacturer. It is engaged in manufacturing and trading pharmaceutical products. The company produces biologically active food supplements which include food supplements are natural complexes containing minerals, vitamins, dietary fibers, extracts of medicinal herbs, amino acids, and others.

Venus Remedies (BOM:526953) Headlines

No Headlines